Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Payables (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Payables for 15 consecutive years, with $843000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Payables rose 84.06% year-over-year to $843000.0, compared with a TTM value of $843000.0 through Sep 2025, up 84.06%, and an annual FY2024 reading of $516000.0, down 16.23% over the prior year.
  • Payables was $843000.0 for Q3 2025 at Alaunos Therapeutics, up from $285000.0 in the prior quarter.
  • Across five years, Payables topped out at $4.2 million in Q1 2021 and bottomed at $262000.0 in Q1 2025.
  • Average Payables over 5 years is $1.1 million, with a median of $843000.0 recorded in 2025.
  • The sharpest move saw Payables skyrocketed 958.08% in 2021, then crashed 85.56% in 2022.
  • Year by year, Payables stood at $1.4 million in 2021, then rose by 1.54% to $1.4 million in 2022, then crashed by 55.65% to $616000.0 in 2023, then dropped by 16.23% to $516000.0 in 2024, then surged by 63.37% to $843000.0 in 2025.
  • Business Quant data shows Payables for TCRT at $843000.0 in Q3 2025, $285000.0 in Q2 2025, and $262000.0 in Q1 2025.